CN102318829B - Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof - Google Patents
Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof Download PDFInfo
- Publication number
- CN102318829B CN102318829B CN2011102386120A CN201110238612A CN102318829B CN 102318829 B CN102318829 B CN 102318829B CN 2011102386120 A CN2011102386120 A CN 2011102386120A CN 201110238612 A CN201110238612 A CN 201110238612A CN 102318829 B CN102318829 B CN 102318829B
- Authority
- CN
- China
- Prior art keywords
- camellia oil
- compound
- health products
- extract
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a compound camellia oil health product with a function of blood pressure decreasing, and a preparation method thereof. The compound camellia oil health product is prepared from the following components: 50-95 parts of camellia oil, 1-10 parts of a eucommia extract, 2-20 parts of a ginkgo extract, 1-10 parts of a sanchi extract, 2-8 parts of soybean lecithin and 0.5-3 parts of an assistant material. The method comprises the following steps: A, preparing the camellia oil; B, mixing the materials; C, carrying out pressing for the resulting viscous mixture to prepare the soft capsule pills. With the present invention, the comprehensive effect of various components in the compound camellia oil health product is adopted, the good function of blood pressure decreasing is provided.
Description
Technical field
The present invention relates to a kind of camellia oil health products and preparation method thereof, relate in particular to a kind of compound camellia oil health products with antihypertensive function and preparation method thereof.Belong to the functional health care food preparing technical field.
Background technology
Hypertension is the topmost hazards that cause angiocardiopathy, often causes the complication of the internal organs such as the heart, brain, kidney, and human health in serious harm.2010, Chinese hyperpietic's number surpassed 200,000,000, and also continue to increase in the number with 1,000 ten thousand every year.And hypertension no longer is middle-aged and old " patents ", and the hypertensive illness rate of the people below 30 years old has reached 10%, and the trend of rising is higher than the elderly far away.Angiocardiopathy has become first cause of death of China resident, has statistics to show, in the annual 3000000 dead cardiovascular patients of China, 50% is all relevant with hypertension.Therefore improve the understanding to high blood pressure, early prevention, in time treatment are had extremely important meaning.
Modern treatment hypertension medication general sequence is: dietotherapy, tea treatment, health care, Chinese medicine are to use Western medicine at last.In order to control blood pressure, except taking medicine, people have found out various methods.Paying attention to the China of dietotherapy, the food by entrance prevents or improves some disease is common way.Camellia oil refines in Wild Woody oil section fruit, is one of the world's four large xylophyta oil.In fact the dietotherapy dual-use function of China's camellia oil is better than olive oil, except the aliphatic acid composition of two kinds of greases and oil property, nutritional labeling are similar, tea oil also contains the unexistent specific physiological activator Tea Polyphenols of olive oil and camellianin (be TS, or claim Tea Saponin).The content of monounsaturated fatty acids surpasses olive oil, up to 80%; Tea oil is rich in higher vitamin E, is the twice of olive oil." Chinese pharmacopoeia (nineteen ninety-five version) is recorded tea oil as medicinal oil, tea oil is rich in multiple nutritional components because of it, and for oral administration, external application has good effectiveness.Often take, can suppress old and feeble, chronic pharyngitis and prevention human body hypertension, artery sclerosis, disease of cardiovascular system are had good preventive effect.
Unsaturated fatty acid content in the camellia oil is the highest in the present edible oil up to 90%.The oleic acid content that human body is digested and assimilated is higher, and coronary heart disease and Hypertension incidence and the death rate are lower.The resident in long-term edible camellia oil area, coronary heart disease and hyperpietic are few.
Phytosterol is a kind of natural active matter of effective reduction cholesterol, and it can suppress human body to the absorption of cholesterol, plays the reduction cholesterol, the effect of angiocardiopathy preventing.Human body can not synthesizing phytosterol, must obtain from meals, and edible oil is people absorb phytosterol from meals important channel.Because the camellia oil content of phytosterol is low, reduction DeGrain to cholesterol, Chinese patent application (CN101869152A) discloses the preparation method of the refining health-care camellia oil of a plant sterols and camellia oil compatibility, and the sterol total content reaches 10000-15000mg/L in the camellia oil although the method can make.But the health product that adopts single camellia oil to make does not all have the effect that reduces blood pressure significantly, thereby, a kind of compound camellia oil health product with better antihypertensive function take camellia oil as main component need to be provided.
Summary of the invention
The present invention is directed to the existing defective of prior art, provide a kind of compatibility reasonable, the obvious compound camellia oil of blood pressure reduction effect health products.
Another object of the present invention is to provide the preparation method of these compound camellia oil health products.
Compound camellia oil health products of the present invention are made by following component: (consumption is weight portion)
Camellia oil 50-95 eucommia ulmoides extracts 1-10 ginkgo biloba extract 2-20
Notogineng Extract 1-10 soybean lecithin 2-8 auxiliary material: 0.5-3.
Prescription preferred weight (part) ratio range of preparation health products of the present invention is:
Camellia oil 60-90 eucommia ulmoides extracts 1-10 ginkgo biloba extract 4-15
Notogineng Extract 1-10 soybean lecithin 3-6 auxiliary material: 1-2.Auxiliary material is comprised of sucrose fatty ester and vitamin E, and the weight of each composition (part) proportioning is: sucrose fatty ester 0.5-1, vitamin E 0.5-1.
As preferably, described camellia oil contains the phytosterol total amount and is not less than 10000mg/L, and unsaturated fatty acid content is not less than 80%; Described ginkgo biloba extract is ginkgo biloba p.e, and general flavone is not less than 15%, and the total lactone of gingko is not less than 3%; Described Notogineng Extract is Roots of Panax Notoginseng or stem-leaf extract, and total saponin is 10-80%.Described health products are said formulations on any pharmacy; As preferably, described health products are soft capsules.
Based on the camellia oil angiocardiopathy preventing, improve the effect of myocardial function, cooperate the filling liver kidney of bark of eucommia tool, strengthening the bones and muscles, many effects such as hypotensive, the present invention is intended to develop the antihypertensive product of a kind of camellia oil and eucommia ulmoides extracts compound, the eucommia ulmoides extracts that adopts is that the dry bark of the Eucommiaceae plant bark of eucommia is through the chemical extraction gained, be aided with ginkgo biloba extract in treatment coronary heart disease, angina pectoris, uncomfortable in chest, the symptom such as breathe hard has better effect, the obvious regulating blood lipid action of Notogineng Extract and immunological regulation effect, the compound synergistic effect is remarkable, has good blood pressure reduction effect.
The method that above-mentioned each component is made health products soft capsule of the present invention may further comprise the steps:
The preparation of A, camellia oil: the camellia oilseeds through the pulverizing of shelling after the drying, are then steamed stir-fry first again after moistening; Make the camellia oil crude product through squeezing again, by obtaining edible camellia oil after depickling, the washing, the interpolation phytosterol namely gets the refining camellia oil by using finished product in this camellia oil again;
B, batch mixing: with the above-mentioned refining camellia oil by using finished product that makes and ginkgo biloba extract, Notogineng Extract, eucommia ulmoides extracts, soybean lecithin compatibility, then add auxiliary material, at temperature 30-70 ℃, homogeneous batch mixing under the condition of pressure 15MPa-25MPa makes thick shape mixture;
C, above-mentioned thick shape mixture is made the soft capsule pill through pressing.
Wherein adopt fresh camellia oilseeds through after the drying in the steps A, the camellia oilseeds are shelled, be processed into powdery by pulverizer afterwards; Raw material first through steam or spray water moistening after " the wet steaming fried ", make the tea oil crude product through the expeller squeezing again, obtain edible camellia oil by refining procedures such as depickling, washings.By add phytosterol in this tea oil, sterol content is higher than 10000mg/L in the tea oil until detect, and namely gets the refining camellia oil by using finished product.
Pressing prepares the soft capsule pill and adopts common method may further comprise the steps among the step C: the first step, prepare capsule material glue.According to the capsule material formula, gelatin is put into distilled water soak and to make its expansion, dissolve until gelatin and rear unclassified stores is added in the lump, mix; Second step, the glue sheet.The capsule material glue that taking-up prepares is coated on the smooth plate surface, makes thickness even, then with the heating of about 90 ℃ temperature, makes the surface moisture evaporation, and becoming has certain toughness, certain flexible cushion compound is arranged.The 3rd step, the compacting soft capsule.During small lot batch manufacture, with the manual compacting of pelleting mould; During production in enormous quantities, often adopt the automatic rotation rolling capsule machine to produce.
As preferably, dry in the steps A after water content be controlled at 5%-6%, steam and fry temperature and be controlled at 130-140 ℃, steam fry after water content be controlled at 3%-4%.
As preferably, the temperature of homogeneous batch mixing is 40-60 ℃ among the step B, pressure 20MPa.
40-60 ℃ is advanced compound, and the mixing that utilizes between each component is arranged, and temperature is not very high, also can guarantee the chemically stable of each component.And under 20MPa, be easier to the fast homogeneous of sample.Prepare sample by high-pressure homogeneous method, make its each component by dispersion, inhomogeneous three-phase mixture becomes homogeneous, single-phase mixture.Sample is through after the high-pressure homogeneous processing, and average grain diameter reduces, thereby makes stability, absorbability, the functional greatly raising of sample.
The present invention has the following advantages:
1, to select natural plant be raw material in the present invention, and each component is up to specification, utilizes the comprehensive function of various compositions to have antihypertensive function, and is nontoxic to human body.
2, the present invention is nutritious, and without bitter taste, taking convenience meets the regulation of state food health legislation.
3, light disease person can use separately.Heavier illness can be united use with other hypotensor, can greatly reduce the use amount of common hypotensive Western medicine, and result for the treatment of is obvious, and can slow down significantly or eliminate other complication.
For showing that health products of the present invention have hypotensive result for the treatment of, get 50 male SHR rats, evenly be divided into 4 groups according to pressure value and body weight, be model control group, low dose group of the present invention (compound camellia oil 0.5gkg-1), middle dosage group (compound camellia oil 1.0gkg-1) and high dose group (compound camellia oil 2.0gkg-1), every group 10, other gets 10 Wistar rats as Normal group, 4 weeks of successive administration.Administration 1,2,3,4 whens week, after each is organized rat and weighs, measure systolic pressure (SBP), diastolic pressure (DBP), mean pressure (MBP) and heart rate (HR).
Result of the test tentatively shows, the blood pressure of model control group SHR rat is significantly higher than the blood pressure of normal Wistar rats, and raises along with the increase in age in week; The compound camellia oil can significantly suppress the rising of the blood pressure of SHR rat, and the approach of its effect may be to suppress the rising of blood pressure by softening blood vessel.The effect that can suppress the rising of SHR rat of the present invention is described.
1. test objective
Observe the compound camellia oil to the impact of spontaneous hypertensive rat (SHR) blood pressure, hypotensive activity provides preliminary experimental basis to spontaneous hypertensive rat for the compound camellia oil.
2. tested medicine
2.1 trial drug
2.1 title: the compound camellia oil, proterties: buff liquid, date received: 20110402, the unit of providing: Inst. of Subtropical Forestry, Chinese Academy of Forestry Sciences, storage procedures: 4 ℃ of preservations.Compound method: be dissolved to desired concn with 2% sucrose-fatty ester solution before use.
2.2 negative control product
Title: sucrose fatty ester (S-170), Mitsubishi Co., Ltd., lot number is 0Z10940A; 2% sucrose fat ester solution compound method: get the 20g sucrose fatty ester, add 98 ℃ the distilled water of 1000ml, break up with refiner and stir, after the cooling, be stored in 4 ℃.
3. experimental animal
Cultivars and strains: the SHR rat, rank: the SPF level, sex: male, body weight: 10 ages in week, quantity: 50; The Wistar rat, rank: the SPF level, sex: male, body weight: 10 ages in week, quantity: 10; Source: Shanghai Experimental Animal Center/Shanghai Slac Experimental Animal Co., Ltd. of the Chinese Academy of Sciences [production licence: SCXK (Shanghai) 2007-0005].
4. experiment condition
Barrier system experiment receptacle, temperature: 22 ± 1 ℃, humidity: 50-70%, illumination: 150-200Lx, light and shade replaced in 12 hours, noise＜50dB, occupancy permit: SYXK (Zhejiang) 2008-0115.
Drinking-water: the tap water filter sterilization places autoclaved drinking bottle freely to drink.
Feed: full nutrition pellet.
Feeding manner: free diet, give sufficient feed and water in the rat breeding cage, every cage is raised 4 rats, and before the test, every rat is weighed, marker number.
5. reagent and instrument
5.1 reagent and kit
5.1.1 sodium chloride injection, the 250ml/ bottle, content 0.9% is produced by Shapuaisi Pharmaceutical Co., Ltd., Pinghu City, Zhejiang Prov., and lot number is 110108-4;
5.2 instrument and equipment
5.2.1ALC-NIBP the rat tail artery non-invasive blood pressure is measured system, Shanghai Alcott bio tech ltd;
5.2.2MLS-3020 autoclave, SANYO GS Electronics Co., Ltd.;
5.2.3AG204-electronic analytical balance Switzerland METTLER company.
6. grouping and administration
6.1 dosage setting and group
6.1.1 Normal group: 2% sucrose-fatty ester solution 10mlkg-1;
6.1.2 model control group: 2% sucrose-fatty ester solution 10mlkg-1;
6.1.3 compound camellia oil low dose group: compound camellia oil 0.5gkg-1;
Amount group during 6.1.4 the compound camellia oil is low: compound camellia oil 1.0gkg-1;
6.1.5 compound camellia oil high dose group: compound camellia oil 2.0gkg-1.
6.2 dosage arranges according to (human dosage the consigner provide)
Compound camellia oil human dosage uses and is 3g/ days, calculates by body weight for humans 60kg, and human dosage is 0.05gkg-1; Mouse dosage is calculated as 0.5kg-1,1.0gkg-1 and 2.0gkg-1 with 10,20,40 times of clinical dosage.
6.3 administration concentration
6.3.1 compound camellia oil low dose group: compound camellia oil 0.05gml-1;
6.3.2 dosage group in the compound camellia oil: compound camellia oil 0.10gml-1;
6.3.3 dosage group in the compound camellia oil: compound camellia oil 0.20gml-1.
6.4 method of administration and capacity
The oral 10mlkg-1 body weight of gavage, medicine-feeding way and clinical administration approach are basically identical.
7. test method
Get 50 male 10 the week ages the SHR rat raise 20d in advance after, measure blood pressure basic value and body weight, evenly be divided into 4 groups according to pressure value and body weight, it is model control group, compound camellia oil low dose group (compound camellia oil 0.5gkg-1), dosage group in the compound camellia oil (compound camellia oil 1.0gkg-1) and compound camellia oil high dose group (compound camellia oil 2.0gkg-1), every group 10, other gets 10 Wistar rats as Normal group, 2% sucrose-fatty ester solution of Normal group and model control group gavage 10mlkg-1 body weight, each administration group rat oral gavage gives corresponding medicine, 4 weeks of successive administration.Administration 1,2,3,4 whens week, after each is organized rat and weighs, measure systolic pressure (SBP), diastolic pressure (DBP), mean pressure (MBP) and heart rate (HR).
8. observation index
8.1 rat body weight, systolic pressure (SBP), diastolic pressure (DBP), mean pressure (MBP) and heart rate (HR).
9. data are processed
Carry out statistical analysis with SPSS13.0 software, remainder data is with mean ± standard deviation
T test evaluation result of the test is used in expression, measurement data.
10. result of the test
The compound camellia oil is on the impact of spontaneous hypertensive rat body weight
By table 1 result as seen, compare with Normal group, the front body weight of model control group SHR rat administration is apparently higher than rats in normal control group (P＜0.01), and administration 3 week beginning, the model control group rat body weight significantly is lower than rats in normal control group body weight (P＜0.05); With model control group relatively, give 0.5,1.0, the compound camellia oil of 2.0gkg-1 is after 4 weeks, administration group rat body weight have no significant change (P＞0.05).
Table 1: the compound camellia oil on the impact of spontaneous hypertensive rat body weight (g, n=10,
)
Annotate: compare with Normal group,
ΔP＜0.05,
The Δ ΔP＜0.01; With the model control group comparative group,
*P＜0.05,
*P＜0.01.
The compound camellia oil is on the impact of spontaneous hypertensive rat systolic pressure (SBP)
By table 2 result as seen, compare with Normal group, the forward and backward systolic pressure of model control group SHR rat administration is all apparently higher than rats in normal control group systolic pressure (P＜0.01); With model control group relatively, give 0.5,1.0,2.0gkg
-1Compound camellia oil after 4 weeks, high dose group (2.0gkg
-1The compound camellia oil) rat systolic pressure when administration 2,3,4 week significantly reduces (P＜0.05, P＜0.01), middle dosage group (1.0gkg
-1The compound camellia oil) rat systolic pressure when administration 2,4 week significantly reduces (P＜0.05, P＜0.01), low dose group (0.5gkg
-1The compound camellia oil) rat administration 2 during week systolic pressure significantly reduce (P＜0.05).
Table 2: the compound camellia oil on the impact of spontaneous hypertensive rat systolic pressure (SBP) (mmHg, n=10,
)
Annotate: compare with Normal group,
ΔP＜0.05,
The Δ ΔP＜0.01; With the model control group comparative group,
*P＜0.05,
*P＜0.01.
The compound camellia oil is on the impact of spontaneous hypertensive rat diastolic pressure (DBP)
By table 3 result as seen, compare with Normal group, the forward and backward diastolic pressure of model control group SHR rat administration is all apparently higher than rats in normal control group systolic pressure (P＜0.01); With model control group relatively, give 0.5,1.0,2.0gkg
-1Compound camellia oil after 4 weeks, high dose group (2.0gkg
-1The compound camellia oil) rat diastolic pressure when administration 2,3,4 week significantly reduces (P＜0.05, P＜0.01), middle dosage group (1.0gkg-
1The compound camellia oil) rat diastolic pressure when administration 2,4 week significantly reduces (P＜0.05, P＜0.01), low dose group (0.5gkg
-1The compound camellia oil) rat administration 2 during week diastolic pressure significantly reduce (P＜0.05).
Table 3: the compound camellia oil on the impact of spontaneous hypertensive rat diastolic pressure (DBP) (mmHg, n=10,
)
Annotate: compare with Normal group,
ΔP＜0.05,
The Δ ΔP＜0.01; With the model control group comparative group,
*P＜0.05,
*P＜0.01.
The compound camellia oil is on the impact of spontaneous hypertensive rat mean pressure (MBP)
By table 4 result as seen, compare with Normal group, the forward and backward mean pressure of model control group SHR rat administration is all apparently higher than rats in normal control group systolic pressure (P＜0.01); With model control group relatively, give 0.5,1.0,2.0gkg
-1Compound camellia oil after 4 weeks, high dose group (2.0gkg
-1The compound camellia oil) rat mean pressure when administration 2,3,4 week significantly reduces (P＜0.05, P＜0.01), middle dosage group (1.0gkg
-1The compound camellia oil) rat mean pressure when administration 2,4 week significantly reduces (P＜0.05, P＜0.01), low dose group (0.5gkg
-1The compound camellia oil) rat administration 2 during week mean pressure significantly reduce (P＜0.05).
Table 4: the compound camellia oil on the impact of spontaneous hypertensive rat mean pressure (MBP) (mmHg, n=10,
)
Annotate: compare with Normal group,
ΔP＜0.05,
The Δ ΔP＜0.01; With the model control group comparative group,
*P＜0.05,
*P＜0.01.
The compound camellia oil is on the impact of spontaneous hypertensive rat heart rate (HR)
By table 5 result as seen, compare with Normal group, the forward and backward heart rate of model control group SHR rat administration is all apparently higher than rats in normal control group systolic pressure (P＜0.05, P＜0.01); With model control group relatively, give 0.5,1.0,2.0gkg
-1Compound camellia oil after 4 weeks, each administration group rat heart rate number of times have no significant change (P＞0.05).
Table 5: the compound camellia oil on the impact of spontaneous hypertensive rat heart rate (HR) (bpm, n=10,
)
Annotate: compare with Normal group,
ΔP＜0.05,
The Δ ΔP＜0.01; With the model control group comparative group,
*P＜0.05,
*P＜0.01.
Above result of the test tentatively shows, the blood pressure of model control group SHR rat is significantly higher than the blood pressure of normal Wistar rats, and raises along with the increase in age in week; The compound camellia oil can significantly suppress the rising of the blood pressure of SHR rat, and the approach of its effect may be to suppress the rising of blood pressure by softening blood vessel.Illustrate that the compound camellia oil can suppress the effect that the SHR rat raises.
Embodiment: take by weighing raw material (Kg) by table 6 proportioning
Embodiment 1:
The preparation of refining mountain camellia oil
Fresh camellia oilseeds through moisture control after the drying 5%-6% with interior, the camellia oilseeds are shelled, steam after moistening through spraying water and fry, fry the material temperature degree and be controlled at 130-140 ℃, steam fry after water content be 3%-4%.After make the tea oil crude product through expeller squeezing again.By depickling, washing, the refining procedures such as clean flavor obtain edible camellia oil.The unsaturated fatty acid content that detects in the tea oil is not less than 80%, sterol content is not less than 1000mg/L, take by weighing a certain amount of phytosterol by calculating, with a small amount of refining tea oil dissolving, then under agitation add the good phytosterol of dissolving, stir, sterol content is higher than 10000mg/L in the tea oil until detect, and namely gets the refining camellia oil by using finished product.
The preparation of camellia seed oil soft capsule
According to the weight proportion of embodiment in the table 61 with eucommia ulmoides extracts, ginkgo biloba extract, Notogineng Extract, soybean lecithin and sucrose fatty ester add above-mentioned making in the refining camellia oil by using finished product, then add vitamin E, under 50 ℃ and 20MPa, carry out homogeneous, make powder ball shape mixture, adjust soft capsule device to scope of design and carry out pelleting, drying at room temperature two days, reject the defective capsule and pill of outward appearance, the washing capsule and pill is removed surface lubrication oil, obtains the soft capsule semi-finished product, after drying and the cleaning, pick out and detect qualified pill packaging in the plastic-aluminum pressing plate or in the bottle of packing into,, post label, make the hypotensive soft capsule product of camellia oil of the present invention.
The preparation method of embodiment 2-4 repeats no more with embodiment 1.
Specific embodiment described in the present invention only is to the explanation for example of the present invention's spirit.Those skilled in the art can make various modifications or replenish or adopt similar mode to substitute described specific embodiment, but can't depart from spirit of the present invention or surmount the defined scope of appended claims.
Although the present invention has been made a detailed description and has quoted as proof some specific embodiments, to those skilled in the art, only otherwise it is obvious leaving that the spirit and scope of the present invention can make various changes or revise.
Claims (6)
1. the compound camellia oil health products with antihypertensive function is characterized in that it is the product of being made by the raw material of following weight proportion
Camellia oil: 60-90, eucommia ulmoides extracts: 1-10, ginkgo biloba extract: 4-15, Notogineng Extract: 1-10, soybean lecithin: 3-6, auxiliary material: 1-2; Described auxiliary material is comprised of sucrose fatty ester and vitamin E, and the weight proportion of each composition is sucrose fatty ester: 0.5-1, vitamin E: 0.5-1; Described camellia oil contains the phytosterol total amount and is not less than 10000mg/L, and unsaturated fatty acid content is not less than 80%; Described ginkgo biloba extract is ginkgo biloba p.e, and general flavone is not less than 15%, and the total lactone of gingko is not less than 3%; Described Notogineng Extract is Roots of Panax Notoginseng or stem-leaf extract, and total saponin is 10-80%.
2. the compound camellia oil health products with antihypertensive function according to claim 1 is characterized in that described health products are said formulations on any pharmacy.
3. the compound camellia oil health products with antihypertensive function according to claim 2 is characterized in that described health products are soft capsules.
4. preparation method with compound camellia oil health products of antihypertensive function claimed in claim 3, the method may further comprise the steps:
The preparation of A, camellia oil: the camellia oilseeds through the pulverizing of shelling after the drying, are then steamed stir-fry first again after moistening; Make the camellia oil crude product through squeezing again, by obtaining edible camellia oil after depickling, the washing, the interpolation phytosterol namely gets the refining camellia oil by using finished product in this camellia oil again;
B, batch mixing: with the above-mentioned refining camellia oil by using finished product that makes and ginkgo biloba extract, Notogineng Extract, eucommia ulmoides extracts, soybean lecithin compatibility, then add auxiliary material, at temperature 30-70 ℃, batch mixing homogeneous under the condition of pressure 15MPa-25MPa makes thick shape mixture;
C, above-mentioned thick shape mixture is made the soft capsule pill through pressing.
5. the preparation method with compound camellia oil health products of antihypertensive function according to claim 4 is characterized in that dry rear water content is controlled at 5%-6% in the steps A, steams the stir-fry temperature and is controlled at 130-140 ℃, and steaming is fried rear water content and is controlled at 3%-4%.
6. according to claim 4 or 5 described preparation methods with compound camellia oil health products of antihypertensive function, the temperature that it is characterized in that batch mixing homogeneous among the step B is 40-60 ℃, pressure 20MPa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102386120A CN102318829B (en) | 2011-08-17 | 2011-08-17 | Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102386120A CN102318829B (en) | 2011-08-17 | 2011-08-17 | Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102318829A CN102318829A (en) | 2012-01-18 |
| CN102318829B true CN102318829B (en) | 2013-02-20 |
Family
ID=45446773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102386120A Expired - Fee Related CN102318829B (en) | 2011-08-17 | 2011-08-17 | Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102318829B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103651958A (en) * | 2013-11-22 | 2014-03-26 | 安徽大平油脂有限公司 | Health oil with efficacities of activating blood and promoting circulation of Qi |
| CN106262890A (en) * | 2016-08-12 | 2017-01-04 | 贵州省玉屏县金心笛油脂开发有限公司 | A kind of tea oil health-care product with hypolipemic function and preparation method thereof |
| CN106190534A (en) * | 2016-08-16 | 2016-12-07 | 贵州石阡佛顶山野生油茶油业有限公司 | A kind of preparation method of blood pressure lowering Oleum Camelliae |
| CN108812938A (en) * | 2018-07-19 | 2018-11-16 | 芷江华兴油业有限公司 | A kind of tea oil and preparation method thereof |
| CN113632855A (en) * | 2021-06-24 | 2021-11-12 | 中国林业科学研究院亚热带林业研究所 | Pecan oil composition with blood fat reducing function and preparation method thereof |
| CN113615836A (en) * | 2021-06-24 | 2021-11-09 | 中国林业科学研究院亚热带林业研究所 | Cathay hickory oil composition with function of reducing blood pressure and preparation method thereof |
| CN113475713A (en) * | 2021-06-24 | 2021-10-08 | 中国林业科学研究院亚热带林业研究所 | Hickory oil composition with anti-fatigue function and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049380A (en) * | 2007-05-11 | 2007-10-10 | 张冰文 | Enteric solubility soft capsule containing camellia oil, and preparation method |
| CN101810336B (en) * | 2010-04-30 | 2012-03-21 | 广东仙乐制药有限公司 | Chewable soft capsules and method for preparing same |
| CN101869152B (en) * | 2010-06-08 | 2012-11-14 | 华南农业大学 | Health-care camellia oil and preparation method thereof |
| CN101978891A (en) * | 2010-09-02 | 2011-02-23 | 安吉铭鑫茶业科技有限公司 | Ginkgo flavone-containing oil-based oral emulsion and preparation method thereof |
| CN102100873B (en) * | 2011-01-22 | 2012-04-25 | 李文东 | Chinese patent medicine for treating heart cerebrovascular diseases and preparation method thereof |
-
2011
- 2011-08-17 CN CN2011102386120A patent/CN102318829B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102318829A (en) | 2012-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102283386B (en) | Composite camellia oil health care product with function of reducing blood fat and preparation method thereof | |
| CN102318829B (en) | Compound camellia oil health product with function of blood pressure decreasing, and preparation method thereof | |
| JP5121308B2 (en) | Composition for preventing, improving or treating metabolic syndrome | |
| WO2016173509A1 (en) | Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof | |
| CN1470255A (en) | Preparation extracted from the root of red-rooted solvia and pseudo-ginseng and its compound preparation and medical use | |
| CN104664370A (en) | Chewable flax tablet | |
| CN102008077B (en) | Composition and health care food with the lipid-lowering efficacy as well as preparation method thereof | |
| CN107981351A (en) | A kind of meals microcapsule granule for adjusting body fat rate and preparation method thereof | |
| CN102090637A (en) | Collagen-containing compound nutritious powder | |
| KR100419185B1 (en) | Healty food composition for obesity control | |
| CN105433382A (en) | Peruvian ginseng composition as well as preparation method and application thereof | |
| CN109380728B (en) | Composition and health food with auxiliary blood pressure lowering effect | |
| CN101850028B (en) | Composition with function of relieving visual fatigue | |
| CN100465255C (en) | Eucommia oil and alpha-linolenic acid product prepared by using eucommia oil as raw material | |
| KR101811210B1 (en) | Composition for treatment, improvement or prevention of Diabetes comprising extract of fruit of Sorbus commixta as an effective component | |
| CN108671055A (en) | A kind of Chinese medicine composition of spleen tonifying and fat and preparation method thereof | |
| JP7104267B1 (en) | Cognitive function improver | |
| JP7108992B1 (en) | Composition containing ingredient derived from pericarp of sea buckthorn | |
| JP7505728B2 (en) | Oral Compositions | |
| CN107259012A (en) | A kind of Traditional Chinese medicine health tea for nursing one's health human body energy and preparation method thereof | |
| Arafa et al. | The Potential Effects of Garden Cress Seeds (Lepidium Sativum L.) on the Bone of Female Rats Suffering from Osteoporosis | |
| UA144041U (en) | DIET SUPPLEMENT "ELIKSIR BOYARISHNYK" | |
| KR100450055B1 (en) | Food composition for improving physical constitution containing seeds of bean plants as main components, and food produced therefrom | |
| Batool et al. | Journal of Agriculture and Food Research | |
| CN104490988B (en) | A kind of composition and preparation method thereof and purposes improving menopausal syndrome symptom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130220 Termination date: 20170817 |